Formula I Compounds Inhibit SLPI Secretion to Block Cancer Metastasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for triple negative breast cancer (TNBC) and other cancers associated with high levels of secretory leukocyte protease inhibitor (SLPI) are inadequate in inhibiting metastasis, as SLPI promotes cell invasion and metastasis by interacting with retinoblastoma (Rb) tumor suppressor protein and activating Forkhead box transcriptional factor M1 (FoxM1), leading to aggressive disease progression.
Innovation Solution
Administration of compounds of Formula I, which inhibit SLPI secretion and expression, thereby reducing Rb phosphorylation and FoxM1 activation, thereby inhibiting metastasis in subjects with cancers like TNBC, breast cancer, lung cancer, and colorectal cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for triple negative breast cancer and other cancers associated with high levels of SLPI, then general cancer treatment is provided, but metastasis inhibition is inadequate
Solution Approach 1:
The patent extracts and targets the specific harmful component SLPI from the complex cancer system. By developing compounds that specifically inhibit SLPI secretion and expression, the treatment isolates and addresses the key driver of metastasis without requiring broad-spectrum chemotherapy, thereby improving metastasis inhibition efficacy while reducing unnecessary toxicity.
Solution Approach 2:
The patent changes the biochemical parameters of SLPI by using compounds that alter its secretion levels and expression. The compounds modify the SLPI protein's stability, secretion rate, or expression level, thereby changing the system's metastatic potential parameter from high to low, achieving effective metastasis inhibition.
2Object-generated harmful factors
If SLPI interacts with Rb and activates FoxM1, then cell invasion and metastasis are promoted, but tumor suppressor function is compromised
Solution Approach 1:
The patent applies preliminary anti-action by blocking SLPI secretion and expression before it can interact with Rb and activate FoxM1. The compounds prevent the harmful SLPI-Rb-FoxM1 axis from forming in the first place, thereby protecting tumor suppressor function and preventing cell invasion and metastasis before they occur.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that bind to SLPI or its secretion pathway, preventing SLPI from interacting with its target Rb. These intermediary compounds block the harmful protein-protein interaction between SLPI and Rb, thereby preventing downstream FoxM1 activation and maintaining tumor suppressor function.
3Reliability
If compounds of Formula I are administered to inhibit SLPI secretion, then metastasis is reduced, but drug specificity and selectivity must be maintained
Solution Approach 1:
The patent employs parameter changes by systematically modifying chemical parameters of the compounds (substituents R1, R2, R3, linker L1, and core structure) to optimize both SLPI inhibition potency and selectivity. By adjusting these chemical parameters, the compounds achieve high metastasis inhibition efficacy while maintaining appropriate selectivity for SLPI over other proteins.
Solution Approach 2:
The patent creates a universal compound scaffold (Formula I) that can inhibit SLPI across multiple cancer types (breast, lung, gastric, colorectal cancers). The core structure with variable substituents provides multi-functionality, allowing the same basic compound framework to address SLPI-mediated metastasis in different cancer contexts while maintaining structural consistency and mechanism of action.
Data Source
AI summary
This invention relates to compounds that are useful for inhibiting the secretion of secretory leukocyte protease inhibitor (SLPI) in a subject. Methods of inhibiting metastasis of cancer and methods of treating cancer in a subject are also provided.